Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.02 | N/A | +2.57% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.57% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their pharmaceutical pipeline while acknowledging some headwinds in consumer health. They emphasized their commitment to long-term growth.
Management highlighted ongoing strength in their pharmaceutical segment.
They noted challenges in consumer health products but remain focused on innovation.
This earnings report shows that Johnson & Johnson was able to exceed earnings expectations, particularly driven by their pharmaceutical division. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the earnings beat could indicate positive momentum in the company's core areas.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HDFC BK LTD ADR
Jan 22, 2019